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Summary.-An evaluation of iron metabolism has been carried out in 23 untreated
patients with Hodgkin's disease and 6 patients with other lymphomata. The
reduction in red cell life span is related to the stage ofthe disease. There is an almost
universal impairment of iron release from the reticuloendothelial system with a
consequent sideropenia and failure of iron delivery to the bone marrow for erythro-
poiesis. This defect is found in all stages ofthe disease and is not related to systemic
symptoms.
ABNORMALITIES in iron metabolism
characterized by an increase in marrow
reticuloendothelial iron, low plasma iron
and transferrin concentration with a
corresponding reduction in transferrin
saturation are a common feature of
generalized Hodgkin's disease. Iron kine-
tic studies using 59Fe labelled transferrin
have shown that a diminished turnover
time is also a common feature and that
the plasma iron turnover may be reduced,
normal or increased (Giannopoulos and
Bergsagel, 1959; Cline and Berlin, 1963).
When 59Fe haemoglobin is injected intra-
venously it is rapidly cleared by the
reticuloendothelial (RE) system and
studies of radioactive iron utilization
following its administration have shown
diminished red cell incorporation in
patientswithgeneralizedHodgkin'sdisease
(Haurani, Young and Tocantins, 1963).
This is thought to be due to a failure of
RE cells to release iron derived from the
catabolism of haemoglobin, and this state
is associated with a low plasma iron
concentration and consequent impaired
delivery to the bone marrow (Cartwright
and Lee, 1971). An alternative method
of measuring RE cell iron release involves
a double isotope technique in which
55Fe labelled iron dextran replaces labelled
haemoglobin and 59Fe labelled transferrin
is used to measure plasma iron utilization
(Beamish et al., 1971). Defective RE
release of iron in Hodgkin's disease has
also been demonstrated by this technique,
which has the advantage of eliminating
the difficulties associated with intravenous
infusion oflabelled haemoglobin solutions.
Previous studies carried out to define
the abnormalities of iron metabolism in
Hodgkin's disease have been performed
on small numbers of selected patients,
usually with advanced generalized disease
and often following treatment with radio-
therapy or chemotherapy. The present
day use of lymphangiography, tomo-
graphy, and diagnostic laparotomy has
allowed the clinician to stage the disease
with increasing accuracy. The present
study was undertaken to define more
precisely the abnormalities in iron meta-
bolism in untreated cases and to relate
these changes to the extent of the disease
at the time of diagnosis as judged by the
clinical stage.
PATIENTS AND METHODS
A total of 29 new patients (22 male and 7
female) were studied. Alymph node biopsy
was taken in each case and on this basis 23
patients were diagnosed as Hodgkin's diseaseIRON METABOLISM IN HODGKIN S DISEASE
and 6 patients as either lymphosarcoma (3),
reticulum cell sarcoma (2) or Brill-Symmers
disease (1). Each patient with Hodgkin's
disease was classified into Stages 1, 2, 3 or 4
with the aid of mediastinal tomography,
abdorniinal lymphangiography, liver and
spleen scanniing using technicium 99 m and
placed into Groups A or B according to the
absence or presence of generalized symptoms
offever, pruritus or night sweats (Rosenberg,
1966). For the purpose of the study the
patients were divided into a Hodgkin's
disease group and a non-Hodgkin's
lymphoma group. Besides classification into
stages, the Hodgkin's disease group was also
arbitrarily divided into a localized group
(Stages IA or 2A) and a generalized group
(Stages iB, 2B, 3 or 4). Haemoglobin (Hb)
concentration, haematocrit, mean corpu-
scular volume (MCV), mean corpuscular
haemoglobin concentration (MCHC) anddirect
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antiglobulin tests were performed by standard
methods (Dacie and Lewis, 1968). Serum
iron (SI) and total iron-biniding capacity
(TIBC) were measured by the method of
Young and Hicks (1965) using magnesium
carbonate as absorbent. A sternal marrow
aspirate was obtained from each patient and
the stainable iron graded from 0 to 6 accord-
ing to Rath and Finch (1948). One iron
deficient patient with absent stainable iron
was excluded from the study. Stainable
reticuloendothelial iron appearedtobepresent
in larger amounts in patients with Stage 3 and
4 disease than in those with Stages 1 and 2.
Radio-isotope studies.-Radioiron studies
were performed on each patient and on 12
healthy volunteers whose consent had been
obtained. The 59Fe labelled transferrin was
prepared in vitro from the subject's own
plasma by the method of Cavill (1971). The
55Fe labelled iron dextran was prepared by
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FIcG. 1.-Haemoglobin concentrations in normal subjects andcl patients with Hodgkin's disease.
Open circles indicate relapse within 4 months of radliotherapy. Mean values indicated by a
horizontal bar.
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Fie1. 2.-Serum iron concentrations in normal subjects and patients w%ith Hodgkin's disease. Open
circles indicate relapse wvithin 4 months of radiotherapy. MIean values in(licated by a horizontal
bar.
Dr G. Moss of Fisons Pharmaceuticals Ltd.
Each subject was given an intravenous
injection of 5 ml of plasma containing 59Fe
transferrin w%%ith an activity of 1 uCi. A
simultaneous intravenous injection of 0 15 ml
of 55Fe iron dextran with an activity of
between 1 and 3 yLCi was also given to 17
patients and 12 normal subjects. Radio-
chromium studies were performed on 11
patients by labelling their own cells with
5ICr sodium chromate (Dacie and Lewis,
1968). Blood samples were taken at 10, 20,
30, 60 and 90 min intervals for estimation
of 59Fe activity. Subsequent samples were
taken at 1, 4, 7, 10, 14, 18 and 21 day intervals
for whole blood 51Cr activity. The 55Fe and
59Fe whole blood activity were also measured
on the 14 days samples by a modification of
the method of Eakins and Brown (1966).
The fractional clearance rate of 59Fe in the
plasma (k) was calculated from the regression
of activity against time, and expressed as the
turnover time (1/k) in min. The plasma
iron turnover (PIT) was calculated from the
formula:
PIT (mg iron/100 ml blood/24 hours)
SI (,ug/100 ml) x k x 1440
X
(100 - PCV)
100
The °,/ transferrin iron utilization 14 days
after injection of 59Fe transferrin was
calculated from the formula:
iron utilization
=red-cell volume (ml)
x 59Fe activity/ml red cells x 100
Total 59Fe activity injected
The red-cell volume wvas directly estimated
from in vivo dilution of 5'Cr labelled red cells
(Dacie and Lewis, 1968) in cases which had
been labelled with 5'Cr and from the tables
of Nadler, Hidalgo and Bloch (1962) in the
remaining cases. The iron dextran
utilization was calculated in a similar manner
14 days after injection of 55Fe iron dextran.
The RE iron release at 14 days wascalculated:
RE iron release
/% iron dextran utilization
transferrin iron utilization x
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The erythrocyte iron turnover (EIT) was
calculated from the formula:
EIT (mg iron/100 ml blood/24 hours)
= transferrin iron utilization x PIT
The red cell survival was expressed as red
cell 51Cr T' in days anid calculated from the
regression of log whole blood activity against
time.
RESULTS
Haemoglobin concentration
The mean haemoglobin concentration
in the entire Hodgkin's disease group was
13*5 g/100 ml and in the iion-Hodgkin's
group 13 6 g/100 ml (Table I). Both are
significantly less than the normal con-
trols (P < 0 01 and <0 05 respectively).
Patients with Stage I disease have nornmal
concentrations (Fig. 1) and significantly
decreased concentrations are found with
more widespread disease and in the
patients with symptomns of generalized
involvement.
Serum iron and transferrin saturation
The mean values are shown in Table I
and the individual results for serum iron
concentrations in Fig. 2. They are signi-
ficantly reduced in both the Hodgkin's
disease and non-Hodgkin's lymphoma
groups (P < 0 001). The decrease in the
serum iron level is related to the clinical
staging of the disease at diagnosis. There
is a significant reduction in Stage I
disease compared with normal (P < 0.025)
although only one result is outside the
normal range. The mean serum iron
level in the localized group differs signi-
ficantly from that in the generalized
group (86.7 + 8&2 g/100 ml and 48-7 ± 4-6
g/100 ml respectivelv; P < 0.001) though
there is some overlap in the individual
values (Fig. 2). The mean 00 transferrin
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Fic. 3. Plasmna ir'oIn turnover time in normal subjects andl patients with Hodgkin's disease. Open
circles indicate relapse within 4 months of radiotherapy. Mean values indicated by a horizontal
bar.
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saturation shows a similar but less marked
decrease, with a significant difference
between the localized and generalized
groups but not between the normal and
localized groups.
Plasma iron turnover time
The values in Stage 1 disease are all
within the normal range and the mean
value is not significantly different from
normal (Table I). The turnover time ofall
but one case is diminished in Stages 3 and
4, there being no overlap with Stage 1
(Fig. 3). The turnover times in Stage 2
are either normal or decreased and it is
notable that they are significantly de-
creased in those patients in Stage 2 who
relapsed within 4 months of radiotherapy,
possibly indicating incorrect staging at
the time of diagnosis (Fig. 3). These
patients all had symptoms and were
therefore placed in the generalized group.
With the exception of one case, all the
values for the localized group are within
the normal range and all those for the
generalized group decreased, the mean
values being 99*9 ± 7-95 and 50 4 + 3 05
min.
Plasma iron turnover and transferrin iron
utilization
The PIT is above the normal range in
2 cases and below in all 11 of the 29
patients studied. There is no significant
difference between the PIT ofthe localized
(0.72 + 0 05 mg/100 ml blood/24 hours)
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FIG. 4. Reticuloendothelial iron release in normal subjects an(l patients w-vith Hodgkin's disease.
Open circles indlicate relapse within 4 months of radiotherapy. 'Mean values indicate(d by a
horizontal bar.
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and the generalized (0.916 + 0 09 mg/100
ml blood/24 hours) groups. There is no
significant difference between transferrin
iron utilization in the localized and
generalized groups or between different
disease stages.
Reticuloendothelial iron release
The mean value for each group is
shown in Table I. Only 2 of the 15 cases
of Hodgkin's disease studied fell within
the normal range. It is significant that
the RE iron release was low in the 3 out
of4 Stage I cases in which it was measured
(Fig. 4). There is no significant difference
between the mean values of the localized (44.6 ± 9.6%) and the generalized group (39.2 i 5.4oo). The RE iron release was
normal in the 2 non-Hodgkin's lymphoma
group cases in which it was estimated.
Red cell survival
Red cell survival is progressively
reduced with each stage in the advance of
the disease (Table I). The 51Cr half time
is 28-8 days in Stage 1 and 21-0 days in
Stage 4. The mean value for patients in
the localized group is 27-7 ± 0-96 days
and 23-9 i 1-96 days for those in the
generalized group. The 2 patients with
values of below 22 days had generalized
Hodgkin's disease. The red cell survival
showed a significant negative correlation
with the PIT (r =-0.7, P < 0.005).
DISCUSSION
A haemoglobin concentration less than
12-0 g/100 ml was found in 5 of the 29
patients. The mean haemoglobin con-
centration in patients with localized
disease (Stages IA and 2A) was not
significantly different from that ofnormal
subjects but there was a significantly
lower haemoglobin concentration in those
with generalized disease. The incidence
ofanaemia is comparable to that found by
Levinson et al. (1957) who found that 22%
of their untreated patients had a haema-
tocrit below 3500.
The mechanisms which have been
proposed to account for the anaemia of
Hodgkin's disease are uncompensated
haemolysis, ineffective erythropoiesis and
a reticuloendothelial block in iron release.
A shortened red cell survival is a common
finding inthegeneralized disease. Astudy
ofthe data takenfrom the series ofNajean,
DreschandArdaillou(1967), ClineandBer-
lin (1963) and Giannopoulos and Bergsagel
(1959), in which a total of 16 cases of
advanced generalized Hodgkin's disease
were studied using 51Cr labelled red cells,
has shown that the red cell survival was
diminished in 90%0 of the cases, with a
mean red cell 51Cr T4 of 17 days. In the
present series, the 51CrTj is within normal
limits in the 4 cases oflocalized Hodgkin's
disease but below 22 days in 2 of the 4
cases of generalized Hodgkin's disease in
which it was examined. The mechanism
of the haemolysis is uncertain. The
presence of spherocytes and a positive
direct antiglobulin test was found in only
one case in the present series, suggesting
that increased haemolysis is rarely due to
an autoimmune process. Previousworkers
have attributed the increased haemolysis
to hyperplasia of reticuloendothelial cells
often associated with splenomegaly (Hoff-
brand, 1964). The extent to which hae-
molysis contributes to anaemia is difficult
to assess. There is no significant correla-
tion between haemoglobin concentration
and 51Cr T' in the present series. There
is, however, a significant negative correla-
tion between the 51Cr T' and the PIT,
suggesting that the previously reported
high PIT in Hodgkin's disease (Gianno-
poulos and Bergsagel, 1959) is consequent
upon the increased erythroid proliferation
in the marrow compensating for hae-
molysis.
Ineffective erythropoiesis with im-
paired incorporation of iron into circula-
ting erythrocytes has been reported by
Cline and Berlin (1963). They studied 8
patients and found substantially reduced
erythrocyte iron turnover, with normal
or elevated plasma iron turnover, in 3
patients with disease. Other workers
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have reported normal or increased trans-
ferrin iron utilization (Haurani et al.,
1963; Najean et al., 1967). In the present
study, transferrin iron utilization was not
significantly different from normal, nor
were abnormal values found in any
sub-group, indicating that neither de-
pressed nor ineffective erythropoiesis is
a significant feature of the disease.
An impaired ability of the RE cell to
release iron is a feature of chronic disease
(Cartwright and Lee, 1971). The conse-
quent defect in reutilization of haemo-
globin iron is characterized by a low
serum iron concentration, a low or normal
total iron binding capacity, decreased
plasma iron turnover time and increased
reticuloendothelial iron stores. This de-
fect has been directly measured in dogs
with turpentine abscesses following the
transfusion ofradioiron labellednon-viable
red cells (Freireich et al., 1957). Haurani
et al. (1963) used 59Fe labelledhaemoglobin
solution prepared by incubating 90 ml of
blood with an increased reticulocyte count
with 59Fe ferrous citrate, which was then
given to patients by intravenous infuision.
The present study has made use of 55Fe
iron dextran as an alternative to hae-
moglobin or red cells to study RE cell iron
release as it has the advantages of being a
stable compound, convenient for clinical
use, with none of the disadvantages and
dangers associated with the transfusion
of relatively large quantities of haemo-
globin solution or senescent red cells.
Iron dextran is rapidly cleared from the
circulation into RE cells and the iron
released behaves in a similar manner to
that released from haemoglobin (Hender-
son and Hillman, 1969). Previous studies
have established this method as a valid
procedure for the estimation of RE iron
release (Beamish et al., 1971).
A defect of RE iron release in general-
ized Hodgkin's disease has been demon-
strated in earlier work. Haurani et al.
(1963) reported a mean haemoglobin iron
reutilization of 31 0 in 5 patients with
Hodgkin's disease compared with a normal
mean value of 70°,. Najean et al. (1967),
using radioiron labelled mouse haemo-
globin, found diminished reutilization in
8 cases of generalized disease and normal
values in 4 cases with localized disease.
The results of the present study indicate
that impaired RE release of iron is an
early feature of Hodgkin's disease, occurr-
ing in both the localized and generalized
groups. The impaired RE release of iron
is associated with a low serum iron level
and diminished plasma iron turnover time,
indicating a relative deficiency in delivery
ofiron to the bone marrow. Thesechanges
become increasingly marked with more
advanced disease. The most significant
abnormality in Stage 1 is a diminished
percentage RE iron release. The mean
serum iron concentration is significantly
reduced though individual values show
considerable overlap with the normal
range. The percentage RE iron release,
serum iron, and plasma iron, turnover
time were, with 2 exceptions, diminished
in Stages 3 and 4. The individual values
for the plasma iron turnover time in
Stage 2 are particularly noteworthy.
Those patients with decreased values
relapsed with palpable lymph nodes in
non-irradiated areas within 4 months of
local radiotherapy, suggesting the presence
of unsuspected lymph node involvement
at the outset. The serum iron values in
these patients show a similar but less clear
cut difference. The decreased plasma iron
turnover times in patients with generalized
disease show virtually no overlap with the
greater turnover times of those with
localized disease.
In the present study, transferrin satur-
ation was below 15%o in 9 out of 29
patients, of whom 8 had generalized
disease. The mean PIT values in these
cases is significantly lower than in those
with a saturation ofabove 15%, indicating
a diminished delivery of iron to the
erythroid marrow with resulting iron
deficient erythropoiesis. The results indi-
cate the absence of any intrinsic defect in
erythropoiesis as judged by normal utiliza-
tion of transferrin bound radioiron. The
most consistent finding, a failure of the
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RE cell to release iron, is seen in both
localized and generalized disease, reflect-
ing a generalized abnormality of the RE
system which appears early in the evolu-
tion of the disease. This abnormality is
also associated with an increase in red cell
destruction in some cases. Thetwo pheno-
mena give a reduction in haemoglobin
concentration due to a haemolytic state
only partially compensated because of
iron deficiency erythropoiesis.
This study was assisted by a grant
from the Leukaemia Research Fund.
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